Approval Year
| Substance Class |
Protein
Created
by
admin
on
Edited
Tue Apr 01 18:28:22 GMT 2025
by
admin
on
Tue Apr 01 18:28:22 GMT 2025
|
| Protein Sub Type | |
| Sequence Origin | HUMAN |
| Sequence Type | COMPLETE |
| Record UNII |
3T7136LE8K
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
3T7136LE8K
Created by
admin on Tue Apr 01 18:28:22 GMT 2025 , Edited by admin on Tue Apr 01 18:28:22 GMT 2025
|
PRIMARY | |||
|
P35348
Created by
admin on Tue Apr 01 18:28:22 GMT 2025 , Edited by admin on Tue Apr 01 18:28:22 GMT 2025
|
PRIMARY | |||
|
P35348
Created by
admin on Tue Apr 01 18:28:22 GMT 2025 , Edited by admin on Tue Apr 01 18:28:22 GMT 2025
|
PRIMARY | |||
|
ALPHA-1_ADRENERGIC_RECEPTOR
Created by
admin on Tue Apr 01 18:28:22 GMT 2025 , Edited by admin on Tue Apr 01 18:28:22 GMT 2025
|
PRIMARY |
| From | To |
|---|---|
| 1_99 | 1_176 |
| Glycosylation Type | HUMAN |
| Glycosylation Link Type | Site |
|---|---|
| N | 1_7 |
| N | 1_13 |
| N | 1_22 |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
AGONIST -> TARGET | |||
|
|
INHIBITOR -> TARGET |
Ki
|
||
|
INHIBITOR -> TARGET | |||
|
|
INHIBITOR -> TARGET | |||
|
|
AGONIST -> TARGET |
|
||
|
INHIBITOR -> TARGET |
Selectivity of silodosin determined in cloned human ?1-adrenergic receptor (?1-AR) subtypes in cultured Chinese hamster ovary cells.Silodosin has greater affinity for the ?1A-adrenergic receptor than for the ?1B-adrenergic receptor (by a factor of 583), minimizing the propensity for blood pressure-related adverse effects mediated by ?1B blockade.
Ki
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET | |||
|
INHIBITOR -> TARGET | |||
|
AGONIST -> TARGET | |||
|
|
AGONIST -> TARGET |
Highly selective ?1-adrenoceptor agonist that is approximately four times more potent than phenylephrine at constricting porcine IAS tissue in vitro.
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET | |||
|
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
|
||
|
|
INHIBITOR -> TARGET | |||
|
|
INHIBITOR -> TARGET | |||
|
RADIOLIGAND->TARGET |
BINDING
Kd
|
||
|
|
INHIBITOR -> TARGET |
Ki
|
||
|
AGONIST -> TARGET | |||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
BINDING
IC50
|
||
|
AGONIST -> TARGET |
|
||
|
|
AGONIST -> TARGET | |||
|
INHIBITOR -> TARGET |
INHIBITOR
Ki
|
||
|
AGONIST -> TARGET | |||
|
|
INHIBITOR -> TARGET |
|
||
|
AGONIST -> TARGET | |||
|
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET | |||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
BINDING
IC50
|
||
|
INHIBITOR -> TARGET |
|
||
|
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET | |||
|
AGONIST -> TARGET | |||
|
|
INHIBITOR -> TARGET | |||
|
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
|
AGONIST -> TARGET |
|
||
|
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET | |||
|
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET |
|
||
|
AGONIST -> TARGET | |||
|
INHIBITOR -> TARGET |
BINDING
IC50
|
||
|
RADIOLIGAND->TARGET |
REPRESENTIVE ALPHA-1 ADRENERGIC RECEPTOR
Ki
|
Structural Modifications
| Modification Type | Location Site | Location Type | Residue Modified | Extent | Fragment Name | Fragment Approval |
|---|---|---|---|---|---|---|
| AMINO ACID SUBSTITUTION | [1_215] | DEXFOSFOSERINE | VI4F0K069V |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Molecular Formula | CHEMICAL |
|
||||
| MOL_WEIGHT | CHEMICAL |
|